

Flavio G Rocha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5390498/publications.pdf>

Version: 2024-02-01

99
papers

1,904
citations

304368

22
h-index

301761

39
g-index

102
all docs

102
docs citations

102
times ranked

2581
citing authors

#	ARTICLE	IF	CITATIONS
1	Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?. <i>Hepatology</i> , 2012, 56, 1352-1360.	3.6	229
2	Dual-modality drainage of infected and symptomatic walled-off pancreatic necrosis: long-term clinical outcomes. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 929-935.	0.5	138
3	Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival. <i>Annals of Surgical Oncology</i> , 2014, 21, 1530-1537.	0.7	127
4	Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 490-496.	1.4	111
5	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 134.	2.2	54
6	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, 270, 422-433.	2.1	53
7	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm after curative resection: A multi-institutional study of 392 cases. <i>Journal of Surgical Oncology</i> , 2019, 120, 1071-1079.	0.8	47
8	Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. <i>ESMO Open</i> , 2020, 5, e000668.	2.0	45
9	Validation of Fistula Risk Score calculator in diverse North American HPB practices. <i>Hpb</i> , 2017, 19, 508-514.	0.1	43
10	Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. <i>Journal of Surgical Oncology</i> , 2020, 121, 480-485.	0.8	40
11	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. <i>Surgery</i> , 2019, 165, 548-556.	1.0	39
12	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. <i>Annals of Surgical Oncology</i> , 2019, 26, 2517-2524.	0.7	38
13	Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2018, 117, 868-878.	0.8	36
14	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e28-e35.	2.1	36
15	The conundrum of ≤ 2 -cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. <i>Surgery</i> , 2019, 166, 15-21.	1.0	34
16	Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. <i>Annals of Surgical Oncology</i> , 2017, 24, 1722-1730.	0.7	33
17	Oncoplastic breast conserving surgery is associated with a lower rate of surgical site complications compared to standard breast conserving surgery. <i>American Journal of Surgery</i> , 2019, 217, 138-141.	0.9	33
18	Extreme oncoplasty: Expanding indications for breast conservation. <i>American Journal of Surgery</i> , 2019, 217, 851-856.	0.9	32

#	ARTICLE	IF	CITATIONS
19	What is a better predictor of clinically relevant postoperative pancreatic fistula (CR-POPF) following pancreaticoduodenectomy (PD): postoperative day one drain amylase (POD1DA) or the fistula risk score (FRS)?. <i>Hpb</i> , 2017, 19, 75-81.	0.1	30
20	Association of preoperative monocyte to lymphocyte and neutrophil to lymphocyte ratio with recurrence-free and overall survival after resection of pancreatic neuroendocrine tumors (USâ€NETSG). <i>Journal of Surgical Oncology</i> , 2019, 120, 632-638.	0.8	30
21	Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. <i>Journal of Surgical Oncology</i> , 2019, 120, 231-240.	0.8	29
22	Resectability of colorectal liver metastases: an evolving definition. <i>Hpb</i> , 2012, 14, 283-284.	0.1	28
23	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2020, 121, 1201-1208.	0.8	23
24	Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 122-134.	0.9	22
25	Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer. <i>Annals of Surgery</i> , 2016, 263, 376-384.	2.1	21
26	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 1203-1212.	0.7	21
27	Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. <i>Journal of Surgical Oncology</i> , 2020, 121, 1067-1073.	0.8	21
28	Neuroendocrine Tumors of the Pancreatobiliary and Gastrointestinal Tracts. <i>Surgical Clinics of North America</i> , 2020, 100, 635-648.	0.5	21
29	Oncoplastic reduction mammoplasty, an effective and safe method of breast conservation. <i>American Journal of Surgery</i> , 2018, 215, 910-915.	0.9	20
30	Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. <i>Journal of Surgical Oncology</i> , 2019, 120, 1302-1310.	0.8	20
31	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. <i>Hpb</i> , 2020, 22, 215-223.	0.1	20
32	Classification and techniques of en bloc venous reconstruction for pancreaticoduodenectomy. <i>Hpb</i> , 2016, 18, 827-834.	0.1	19
33	Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multi-institutional analysis. <i>Journal of Surgical Oncology</i> , 2019, 120, 1080-1086.	0.8	18
34	Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. <i>Journal of Surgical Oncology</i> , 2019, 120, 262-269.	0.8	18
35	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. <i>Hpb</i> , 2021, 23, 413-421.	0.1	18
36	Local resection for duodenal gastrointestinal stromal tumors. <i>American Journal of Surgery</i> , 2016, 211, 867-870.	0.9	16

#	ARTICLE	IF	CITATIONS
37	Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?. <i>Journal of Surgical Oncology</i> , 2018, 117, 1655-1663.	0.8	16
38	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. <i>Surgery</i> , 2019, 165, 657-663.	1.0	16
39	Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin. <i>Annals of Surgical Oncology</i> , 2022, 29, 5462-5473.	0.7	16
40	Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 651-658.	0.9	15
41	Clinical relevance of performing endoscopic ultrasoundâ€guided fineâ€needle biopsy for pancreatic neuroendocrine tumors less than 2â€cm. <i>Journal of Surgical Oncology</i> , 2020, 122, 1393-1400.	0.8	15
42	The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. <i>PLoS ONE</i> , 2016, 11, e0150195.	1.1	15
43	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. <i>Hpb</i> , 2020, 22, 1149-1157.	0.1	13
44	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2022, 275, e773-e780.	2.1	13
45	Preoperative computed tomography scan toâ€predict pancreatic fistula after distal pancreatectomy using gland and tumor characteristics. <i>American Journal of Surgery</i> , 2016, 211, 871-876.	0.9	12
46	Surgical strategies and novel therapies for locally advanced pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 16-24.	0.8	12
47	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. <i>Neuroendocrinology</i> , 2021, 111, 129-138.	1.2	12
48	Gastric carcinoids: Does type of surgery or tumor affect survival?. <i>American Journal of Surgery</i> , 2019, 217, 937-942.	0.9	11
49	Modified Appleby procedure for locally advanced pancreatic cancer. <i>American Journal of Surgery</i> , 2018, 215, 853-855.	0.9	10
50	Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?. <i>Journal of Surgical Oncology</i> , 2019, 120, 919-925.	0.8	10
51	Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2225-2231.	0.9	10
52	Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. <i>American Journal of Surgery</i> , 2017, 213, 94-99.	0.9	9
53	Primary and metastatic melanoma of the GI tract: clinical presentation, endoscopic findings, and patient outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 4456-4462.	1.3	9
54	Oncoplastic Breast-Conserving Surgery: Can We Reduce Rates of Mastectomy and Chemotherapy Use in Patients with Traditional Indications for Mastectomy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2199-2209.	0.7	8

#	ARTICLE	IF	CITATIONS
55	Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2017, 35, 365-365.	0.8	8
56	Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine, 2019, 8, 1205.	1.0	7
57	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. American Surgeon, 2019, 85, 1334-1340.	0.4	7
58	Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma?. Hpb, 2018, 20, 925-931.	0.1	6
59	Oncoplastic Central Partial Mastectomy and Neareolar Reduction Mammoplasty with Immediate Nipple Reconstruction: An Initial Report of a Novel Option for Breast Conservation in Patients with Subareolar Tumors. Annals of Surgical Oncology, 2019, 26, 4284-4293.	0.7	6
60	Evaluating Need for Additional Imaging and Biopsy After Oncoplastic Breast-Conserving Surgery. Annals of Surgical Oncology, 2020, 27, 3650-3656.	0.7	6
61	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. Cancers, 2021, 13, 2242.	1.7	6
62	Extended right hepatectomy with caudate lobe resection using the hilar "en bloc" resection technique with a modified hanging maneuver. Journal of Surgical Oncology, 2016, 113, 427-431.	0.8	5
63	Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?. Annals of Surgical Oncology, 2018, 25, 1052-1060.	0.7	5
64	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An institution study from the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2019, 119, 5-11.	0.8	5
65	Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. Hpb, 2020, 22, 1042-1050.	0.1	5
66	Appendiceal Neuroendocrine Tumors: Does Colon Resection Improve Outcomes?. Journal of Gastrointestinal Surgery, 2020, 24, 2121-2126.	0.9	5
67	Hybrid Push-Pull Endoscopic and Laparoscopic Full Thickness Resection for the Minimally Invasive Management of Gastrointestinal Stromal Tumors: A Pilot Clinical Study. Gastroenterology Research and Practice, 2015, 2015, 1-7.	0.7	4
68	Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 3147-3153.	0.7	4
69	Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: ileocecectomy Versus Right Hemicolectomy. Journal of Gastrointestinal Surgery, 2022, 26, 1266-1274.	0.9	4
70	Surgical outcomes of gastroenteropancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. Journal of Surgical Oncology, 2022, 126, 689-697.	0.8	4
71	Premalignant Lesions of the Biliary Tract. Surgical Clinics of North America, 2019, 99, 301-314.	0.5	3
72	Intraoperative radiation therapy in early-stage breast cancer: Presence of lobular features is not associated with increased rate of requiring additional therapy. American Journal of Surgery, 2020, 220, 161-164.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Central pancreatectomy with pancreaticogastrostomy reconstruction: A brief report and video technique. American Journal of Surgery, 2020, 219, 828-830.	0.9	3
74	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. American Surgeon, 2019, 85, 1334-1340.	0.4	3
75	Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. Annals of Surgical Oncology, 2020, 27, 3915-3923.	0.7	2
76	Recurrence of Non-Functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model. World Journal of Surgery, 2021, 45, 2134-2141.	0.8	2
77	Oncoplastic breast-conserving therapy and intraoperative radiotherapy for management of carcinoma in situ of the breast: A single-center experience. Breast Journal, 2020, 26, 2391-2394.	0.4	2
78	Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression.. Journal of Clinical Oncology, 2016, 34, 321-321.	0.8	2
79	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in intestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.. Journal of Clinical Oncology, 2018, 36, 694-694.	0.8	2
80	Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2016, 34, 457-457.	0.8	2
81	Circumferential pedicled omental flap for protection of portomesenteric venous reconstruction and gastroduodenal artery stump following pancreatoduodenectomy. American Journal of Surgery, 2017, 213, 983.	0.9	1
82	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. Journal of Surgical Oncology, 2020, 122, 442-449.	0.8	1
83	Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC): Is preoperative chemoradiation (CRT) essential?. Journal of Clinical Oncology, 2013, 31, 236-236.	0.8	1
84	Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC).. Journal of Clinical Oncology, 2013, 31, 4043-4043.	0.8	1
85	Adjuvant therapy (AT) following resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?. Journal of Clinical Oncology, 2017, 35, 373-373.	0.8	1
86	Foreword. Hepatobiliary Surgery and Nutrition, 2019, 8, S1-S1.	0.7	0
87	Small Bowel Necrosis After Colonoscopy. Gastroenterology, 2019, 156, e12-e13.	0.6	0
88	ASO Author Reflections: Oncoplastic Surgery Facilitates Breast Conservation and May Permit More Judicious Chemotherapy Use. Annals of Surgical Oncology, 2021, 28, 2210-2211.	0.7	0
89	Significance of CEACAM6 expression in biliary tract carcinoma.. Journal of Clinical Oncology, 2012, 30, 207-207.	0.8	0
90	Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma.. Journal of Clinical Oncology, 2013, 31, 177-177.	0.8	0

#	ARTICLE	IF	CITATIONS
91	A randomized, open-label, phase I/II trial of gemcitabine plus nab-paclitaxel with or without FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, TPS500-TPS500.	0.8	0
92	Comparative analysis of resected duodenal and ampullary adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 362-362.	0.8	0
93	Overall survival (OS) in stage II resected pancreatic cancer (PC) using gemcitabine (Gem)/taxane adjuvant therapy (Rx): a single-institution experience.. Journal of Clinical Oncology, 2016, 34, e15693-e15693.	0.8	0
94	Gemcitabine/taxane adjuvant therapy in resected pancreatic cancer: A signal of improved survival?. Journal of Clinical Oncology, 2017, 35, 392-392.	0.8	0
95	Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreatic cancer (BRPC): Updated results.. Journal of Clinical Oncology, 2017, 35, e15771-e15771.	0.8	0
96	Impact of insurance status on survival in neuroendocrine tumors: A multi-institutional Study from the U.S. Neuroendocrine Study Group.. Journal of Clinical Oncology, 2018, 36, 371-371.	0.8	0
97	Association of preoperative monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with overall survival after resection of pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2018, 36, 216-216.	0.8	0
98	Gastric carcinoids: Does type of surgery or tumor affect survival?. Journal of Clinical Oncology, 2018, 36, 139-139.	0.8	0
99	Less invasive option for small hepatocellular carcinoma: thermal ablation as first-line therapy?. Bulletin of the American College of Surgeons, 2014, 99, 46-8.	0.3	0